Szilvia Kugler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Szilvia Kugler has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
A Pinter
Semmelweis University Heart and Vascular Center, Budapest, Hungary
1 shared publicationA Szabo
Semmelweis University, Department of Anaesthesiology and Intensive Care, Budapest, Hungary
1 shared publicationAnna‐Mária Tőkés
Department of Pathology, Forensic and Insurance Medicine Semmelweis University Budapest Hungary
1 shared publicationAttila Fintha
Department of Pathology and Experimental Cancer Research Semmelweis University Budapest Hungary
1 shared publication- Attila Oláh
Heart and Vascular Center, Scientific Research Laboratory, Semmelweis University , 68 Városmajor Street, Budapest 1122
1 shared publication - Balázs Sax
Department of Cardiology, Heart and Vascular Center Semmelweis University Budapest Hungary
1 shared publication
Latest Publications
- Open Access
- 16 November 2023
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 11 (11)
Seroconversion after SARS‐CoV‐2 vaccination is protective against severe COVID‐19 disease in heart transplant recipients
Background: Heart transplant (HTX) recipients are prone to develop complications after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Vaccination is often ineffective due to weaker immunogenicity. In this high‐volume single‐center study, we aimed to determine factors influencing seroconversion after vaccination and predictors of severe SARS‐CoV‐2 infection.Methods: Two hundred twenty‐nine HTX recipients were enrolled. Type of the first two vaccine doses included messenger RNA (mRNA), vector, and inactivated vaccines. We carried out analyses on seroconversion after the second and third doses of vaccination and on severity of infection. Antispike protein SARS‐CoV‐2 immunoglobulin G (IgG) was measured after the second and third vaccines and serostatus was defined. Effect of the first two vaccine doses was studied on patients who did not suffer SARS‐CoV‐2 infection before antibody measurement (n = 175). The effectivity of the third vaccine was evaluated among seronegative recipients after the second vaccine (n = 53). Predictors for severe infection defined as pneumonia, hospitalization or death were assessed in all patients who contracted SARS‐CoV‐2 infection (n = 92).Results: 62% of the recipients became seropositive after the second vaccination. Longer time between HTX and vaccination (odds ratio [OR]: 2.35) and mRNA vaccine (OR: 4.83) were predictors of seroconversion. 58% of the nonresponsive patients became seropositive after receiving the third vaccine. Male sex increased the chance of IgG production after the third dose (OR: 5.65). Clinical course of SARS‐CoV‐2 infection was severe in 32%. Of all parameters assessed, only seropositivity before infection was proven to have a protective effect against severe infection (OR: 0.11).Conclusions: We found that longer time since HTX, mRNA vaccine type, and male sex promoted seroconversion after SARS‐CoV‐2 vaccination in HTX recipients. Seropositivity—but not the number of vaccine doses—seemed to be protective against severe SARS‐CoV‐2 infection. Screening of HTX patients for anti‐SARS‐COV‐2 antibodies may help to identify patients at risk for severe infection.
- 16 November 2023
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 11 (11)
Open AccessSeroconversion after SARS‐CoV‐2 vaccination is protective against severe COVID‐19 disease in heart transplant recipients
Background: Heart transplant (HTX) recipients are prone to develop complications after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Vaccination is often ineffective due to weaker immunogenicity. In this high‐volume single‐center study, we aimed to determine factors influencing seroconversion after vaccination and predictors of severe SARS‐CoV‐2 infection.Methods: Two hundred twenty‐nine HTX recipients were enrolled. Type of the first two vaccine doses included messenger RNA (mRNA), vector, and inactivated vaccines. We carried out analyses on seroconversion after the second and third doses of vaccination and on severity of infection. Antispike protein SARS‐CoV‐2 immunoglobulin G (IgG) was measured after the second and third vaccines and serostatus was defined. Effect of the first two vaccine doses was studied on patients who did not suffer SARS‐CoV‐2 infection before antibody measurement (n = 175). The effectivity of the third vaccine was evaluated among seronegative recipients after the second vaccine (n = 53). Predictors for severe infection defined as pneumonia, hospitalization or death were assessed in all patients who contracted SARS‐CoV‐2 infection (n = 92).Results: 62% of the recipients became seropositive after the second vaccination. Longer time between HTX and vaccination (odds ratio [OR]: 2.35) and mRNA vaccine (OR: 4.83) were predictors of seroconversion. 58% of the nonresponsive patients became seropositive after receiving the third vaccine. Male sex increased the chance of IgG production after the third dose (OR: 5.65). Clinical course of SARS‐CoV‐2 infection was severe in 32%. Of all parameters assessed, only seropositivity before infection was proven to have a protective effect against severe infection (OR: 0.11).Conclusions: We found that longer time since HTX, mRNA vaccine type, and male sex promoted seroconversion after SARS‐CoV‐2 vaccination in HTX recipients. Seropositivity—but not the number of vaccine doses—seemed to be protective against severe SARS‐CoV‐2 infection. Screening of HTX patients for anti‐SARS‐COV‐2 antibodies may help to identify patients at risk for severe infection.
- Open Access
- 25 August 2023
- Published by Wiley in Journal of Anatomy
- Vol. 244 (1) , 120-132
Strong desmin immunoreactivity in the myocardial sleeves around pulmonary veins, superior caval vein and coronary sinus supports the presumed arrhythmogenicity of these regions
Myocardial sleeve around human pulmonary veins plays a critical role in the pathomechanism of atrial fibrillation. Besides the well‐known arrhythmogenicity of these veins, there is evidence that myocardial extensions into caval veins and coronary sinus may exhibit similar features. However, studies investigating histologic properties of these structures are limited. We aimed to investigate the immunoreactivity of myocardial sleeves for intermediate filament desmin, which was reported to be more abundant in Purkinje fibers than in ventricular working cardiomyocytes. Sections of 16 human (15 adult and 1 fetal) hearts were investigated. Specimens of atrial and ventricular myocardium, sinoatrial and atrioventricular nodes, pulmonary veins, superior caval vein and coronary sinus were stained with anti‐desmin monoclonal antibody. Intensity of desmin immunoreactivity in different areas was quantified by the ImageJ program. Strong desmin labeling was detected at the pacemaker and conduction system as well as in the myocardial sleeves around pulmonary veins, superior caval vein, and coronary sinus of adult hearts irrespective of sex, age, and medical history. In the fetal heart, prominent desmin labeling was observed at the sinoatrial nodal region and in the myocardial extensions around the superior caval vein. Contrarily, atrial and ventricular working myocardium exhibited low desmin immunoreactivity in both adults and fetuses. These differences were confirmed by immunohistochemical quantitative analysis. In conclusion, this study indicates that desmin is abundant in the conduction system and venous myocardial sleeves of human hearts.
- 25 August 2023
- Published by Wiley in Journal of Anatomy
- Vol. 244 (1) , 120-132
Open AccessStrong desmin immunoreactivity in the myocardial sleeves around pulmonary veins, superior caval vein and coronary sinus supports the presumed arrhythmogenicity of these regions
Myocardial sleeve around human pulmonary veins plays a critical role in the pathomechanism of atrial fibrillation. Besides the well‐known arrhythmogenicity of these veins, there is evidence that myocardial extensions into caval veins and coronary sinus may exhibit similar features. However, studies investigating histologic properties of these structures are limited. We aimed to investigate the immunoreactivity of myocardial sleeves for intermediate filament desmin, which was reported to be more abundant in Purkinje fibers than in ventricular working cardiomyocytes. Sections of 16 human (15 adult and 1 fetal) hearts were investigated. Specimens of atrial and ventricular myocardium, sinoatrial and atrioventricular nodes, pulmonary veins, superior caval vein and coronary sinus were stained with anti‐desmin monoclonal antibody. Intensity of desmin immunoreactivity in different areas was quantified by the ImageJ program. Strong desmin labeling was detected at the pacemaker and conduction system as well as in the myocardial sleeves around pulmonary veins, superior caval vein, and coronary sinus of adult hearts irrespective of sex, age, and medical history. In the fetal heart, prominent desmin labeling was observed at the sinoatrial nodal region and in the myocardial extensions around the superior caval vein. Contrarily, atrial and ventricular working myocardium exhibited low desmin immunoreactivity in both adults and fetuses. These differences were confirmed by immunohistochemical quantitative analysis. In conclusion, this study indicates that desmin is abundant in the conduction system and venous myocardial sleeves of human hearts.
- Open Access
- 1 April 2021
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 10 (Supplement)
Admission lactate level and the GRACE 2.0 score are independent and additive predictors of 30-day mortality of STEMI patients treated with primary PCI - preliminary results of a real-world registry
Type of funding sources: None. Background In many of the current risk estimation algorithms for patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI), heart rate and systolic blood pressure are key predictors. Yet, these parameters may also be influenced by the actual medical treatment / circulatory support, thereby decreasing the discriminatory power of the models. Purpose We aimed to investigate whether venous lactate level, a marker of microcirculatory failure, may have an added prognostic value beyond conventional predictors. Methods In a pilot real-world registry, 174 cases were studied. Venous blood gas analysis was performed in all patients at hospital admission. Nested logistic regression models were built using the extensively validated "Global Registry of Acute Coronary Events" (GRACE) 2.0 score alone (base model) or with the addition of venous lactate level (expanded model) using 30-day all-cause mortality as outcome measure. Independence of predictors (lack of collinearity) was evaluated by the variance inflation factor (VIF). Instead of the insensitive c-statistic, difference in performance of the nested models was analyzed by the likelihood ratio test and the integrated discrimination improvement (IDI). Results The VIF was 1.0684, indicating independence of the measured lactate values from the calculated GRACE 2.0 scores. Both base and expanded models showed high discriminatory power: c-statistic = 0.88 and 0.89, respectively, p = 0.68). Nevertheless, addition of venous lactate level to the GRACE 2.0 score improved predictions of 30-day mortality significantly as assessed by both likelihood ratio test (chi-square = 8.97, p = 0.0027) and IDI (IDI = 0.1029, 95% CI: 0.0002-0.2055, p = 0.0494). Conclusions Abstract Figure. Abstract Figure.
- 1 April 2021
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 10 (Supplement)
Open AccessAdmission lactate level and the GRACE 2.0 score are independent and additive predictors of 30-day mortality of STEMI patients treated with primary PCI - preliminary results of a real-world registry
Type of funding sources: None. Background In many of the current risk estimation algorithms for patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI), heart rate and systolic blood pressure are key predictors. Yet, these parameters may also be influenced by the actual medical treatment / circulatory support, thereby decreasing the discriminatory power of the models. Purpose We aimed to investigate whether venous lactate level, a marker of microcirculatory failure, may have an added prognostic value beyond conventional predictors. Methods In a pilot real-world registry, 174 cases were studied. Venous blood gas analysis was performed in all patients at hospital admission. Nested logistic regression models were built using the extensively validated "Global Registry of Acute Coronary Events" (GRACE) 2.0 score alone (base model) or with the addition of venous lactate level (expanded model) using 30-day all-cause mortality as outcome measure. Independence of predictors (lack of collinearity) was evaluated by the variance inflation factor (VIF). Instead of the insensitive c-statistic, difference in performance of the nested models was analyzed by the likelihood ratio test and the integrated discrimination improvement (IDI). Results The VIF was 1.0684, indicating independence of the measured lactate values from the calculated GRACE 2.0 scores. Both base and expanded models showed high discriminatory power: c-statistic = 0.88 and 0.89, respectively, p = 0.68). Nevertheless, addition of venous lactate level to the GRACE 2.0 score improved predictions of 30-day mortality significantly as assessed by both likelihood ratio test (chi-square = 8.97, p = 0.0027) and IDI (IDI = 0.1029, 95% CI: 0.0002-0.2055, p = 0.0494). Conclusions Abstract Figure. Abstract Figure.
- Open Access
- 1 July 2018
- Published by Akademiai Kiado Zrt. in Orvosi Hetilap
- Vol. 159 (28) , 1135-1145
Új felismerések a pitvarfibrilláció genezisében és fenntartásában: az egyénre szabott kezelés lehetőségei
Atrial fibrillation affects approximately three percent of the adults. Ablation strategies targeting the isolation of the pulmonary veins are the up-to-date cornerstones for atrial fibrillation ablations. However, a one-year success rate of repeated interventions is not more than 70%. Long-term efficacy of catheter ablation is presumably limited by electrical and structural remodeling of the atria, which results in a progressive increase in the duration of atrial fibrillation to become sustained. The potential pathophysiological importance of the epicardial adipose tissue, atrial fibrosis, autonomic nervous system and arrhythmogenic foci are documented by several studies. Increased volume, inflammation induced transformation to fibrosis and myocardial infiltration of atrial subepicardial fat in obese patients result in higher risk of atrial fibrillation development. Changes in atrial autonomic innervation under some conditions including regular physical exercise strongly promote arrhythmogenesis via the mechanism of enhanced triggered activity or abbreviated atrial refractoriness. Individualized management of possible trigger and substrate mechanisms are proposed to provide a novel basis for the effective treatment of atrial fibrillation. Pro-fibrotic signalling pathways can be inhibited by the suppression of renin-angiotensin-aldosterone system. Neuromodulation strategies include renal sympathetic denervation and ganglionic plexi ablation. Anticoagulation therapy has also been shown to reduce the burden of abnormal atrial remodeling. Possible novel catheter ablation techniques are used for right or left atrial linear lesions, scar homogenization and catheter ablation of complex fractionated atrial electrograms, rotors or ectopic foci. Beside these new management strategies, clinical consideration of factors of particular risks as obesity, hyperlipidaemia, hypertension, diabetes and obstructive sleep apnoe are also essential. Orv Hetil. 2018; 159(28): 1135–1145.
- 1 July 2018
- Published by Akademiai Kiado Zrt. in Orvosi Hetilap
- Vol. 159 (28) , 1135-1145
Open AccessÚj felismerések a pitvarfibrilláció genezisében és fenntartásában: az egyénre szabott kezelés lehetőségei
Atrial fibrillation affects approximately three percent of the adults. Ablation strategies targeting the isolation of the pulmonary veins are the up-to-date cornerstones for atrial fibrillation ablations. However, a one-year success rate of repeated interventions is not more than 70%. Long-term efficacy of catheter ablation is presumably limited by electrical and structural remodeling of the atria, which results in a progressive increase in the duration of atrial fibrillation to become sustained. The potential pathophysiological importance of the epicardial adipose tissue, atrial fibrosis, autonomic nervous system and arrhythmogenic foci are documented by several studies. Increased volume, inflammation induced transformation to fibrosis and myocardial infiltration of atrial subepicardial fat in obese patients result in higher risk of atrial fibrillation development. Changes in atrial autonomic innervation under some conditions including regular physical exercise strongly promote arrhythmogenesis via the mechanism of enhanced triggered activity or abbreviated atrial refractoriness. Individualized management of possible trigger and substrate mechanisms are proposed to provide a novel basis for the effective treatment of atrial fibrillation. Pro-fibrotic signalling pathways can be inhibited by the suppression of renin-angiotensin-aldosterone system. Neuromodulation strategies include renal sympathetic denervation and ganglionic plexi ablation. Anticoagulation therapy has also been shown to reduce the burden of abnormal atrial remodeling. Possible novel catheter ablation techniques are used for right or left atrial linear lesions, scar homogenization and catheter ablation of complex fractionated atrial electrograms, rotors or ectopic foci. Beside these new management strategies, clinical consideration of factors of particular risks as obesity, hyperlipidaemia, hypertension, diabetes and obstructive sleep apnoe are also essential. Orv Hetil. 2018; 159(28): 1135–1145.